Author(s): Kucherenko Liudmyla, Derevianko Natalia, Borsuk Serhii, Khromylova Olga, Bihdan Oleksii, Dmytro Skoryna

Email(s): borsuksergejjj@gmail.com

DOI: 10.52711/0974-360X.2025.00429   

Address: Kucherenko Liudmyla, Derevianko Natalia, Borsuk Serhii, Khromylova Olga, Bihdan Oleksii, Dmytro Skoryna
Department of Pharmaceutical, Organic and Bioorganic Chemistry, Zaporizhzhia State Medical and Pharmaceutical University, The City of Zaporizhzhia, Ukraine.
*Corresponding Author

Published In:   Volume - 18,      Issue - 7,     Year - 2025


ABSTRACT:
Cardiovascular diseases are currently the leading cause of death and disability worldwide. Each year, their prevalence and severity continue to grow. As a result, developing new treatments and preventive measures for cardiovascular conditions has become a critical focus in medicine and pharmacy today. Today, drugs in the form of injections are used in most cases for the treatment of patients in hospital conditions. Therefore, an injectable dosage form was created for the new original compound of 1-(ß-phenylethyl)-4-amino-1,2,4-triazolium bromide, which exhibits antihypertensive, antiischemic, and antioxidant properties. The purpose of our work is to develop an optimal method for the quantitative determination of 1-(ß-phenylethyl)-4-amino-1,2,4-triazolium bromide in an injectable dosage form by the method of high-performance liquid chromatography (HPLC). During the research, we used a laboratory sample of a solution for injections with a concentration of 5 mg/ml, the active ingredient is 1-(ß-phenylethyl)-4-amino-1,2,4-triazolium bromide. A standardized substance of 1-(ß-phenylethyl)-4-amino-1,2,4-triazolium bromide with a content of 99.95% was used as a working standard sample. The research was carried out on the basis of the chemical and physical control laboratory of the Technical Control Department, SE "Chemical Reagent Plant" (city of Kharkiv). The main stage of the work was the development of the method of standardization of the active substance by the HPLC method. As a result of the conducted research, an eluent and a column were selected, with the help of which, under certain conditions, it is possible to carry out simultaneous identification and quantitative determination. According to the developed methods, we analyzed all the series prepared in laboratory conditions. During the work, the content of 1-(ß-phenylethyl)-4-amino-1,2,4-triazolium bromide in the injection solution was determined, which is in the range from 4.83 to 5.25 mg in 1 ml. According to the demands of the State Pharmacopoeia of Ukraine, the content of 1-(ß-phenylethyl)-4-amino-1,2,4-triazolium bromide in the injection solution should be from 4.5 mg to 5.5 mg in 1 ml. As can be seen from the above data, the obtained results meet all the demands of the State Pharmacopoeia of Ukraine. Thus, in the course of the work, a method was developed for the quantitative determination of 1-(ß-phenylethyl)-4-amino-1,2,4-triazolium bromide in an injectable dosage form using the HPLC method. The developed method is planned to be used for continuous quality control of the developed dosage form.


Cite this article:
Kucherenko Liudmyla, Derevianko Natalia, Borsuk Serhii, Khromylova Olga, Bihdan Oleksii, Dmytro Skoryna. Development of an Optimal Method for the Quantitative Determination of 1-(ß phenylethyl)-4-amino-1,2,4-triazolium Bromide in a solution for Injection. Research Journal of Pharmacy and Technology. 2025;18(7): 2998-2. doi: 10.52711/0974-360X.2025.00429

Cite(Electronic):
Kucherenko Liudmyla, Derevianko Natalia, Borsuk Serhii, Khromylova Olga, Bihdan Oleksii, Dmytro Skoryna. Development of an Optimal Method for the Quantitative Determination of 1-(ß phenylethyl)-4-amino-1,2,4-triazolium Bromide in a solution for Injection. Research Journal of Pharmacy and Technology. 2025;18(7): 2998-2. doi: 10.52711/0974-360X.2025.00429   Available on: https://rjptonline.org/AbstractView.aspx?PID=2025-18-7-9


REFERENCES:
1.    Metabolitotropic mechanisms of the cardioprotective action of new antianginal and antihypertensive drug "Hypertril" in experimental myocardial ischemia.  Bielenichev І.F., Kucherenko L.І, Nahorna О.О.  Odesa Medical Journal. 2014; 6 (146): 22-26.
2.    Therapy of post-COVID-19 syndrome: improving the efficiency and safety of basic metabolic drug treatment with tiazotic acid (thiotriazoline). Igor Belenichev; Lyudmyla Kucherenko; Sergii Pavlov.  Pharmacia 69(2). – Sofia, Bulgaria, 2022. – P. 509-516.
3.    Use of Thiocetam in the complex therapy of combat contusion of the brain. І. F. Bielenichev, K. Yu. Nerianov, V. І. Chernii, D. А. Sereda, L. I. Kucherenko, N. V. Derevianko, K. І. Kandybei // Current Issues of Pharmaceutical and Medical Science and Practice. - 2023. - Т. 16, No.2 (42). – P. 170-174. - DOI: 10.14739/2409-2932.2023.2.281460.
4.    Development of a method for quantitative determination of the content of 4-amino-4H-1,2,4-triazole impurity in the active pharmaceutical ingredient 1-(β-phenylethyl)-4-amino-1,2,4-triazolium bromide. H. V. Heorhievskii, О. А. Zinchenko, L.I. Kucherenko, L. І. Shapovalova . Farmakom. 2013; 1:  32–37.
5.    Development of a quantitative determination method for the step-by-step control of the production of Hypertril tablets / L.I. Kucherenko, N.V. Parniuk, Z.B. Moriak // Pharmaceutical journal. – 2015. – No. 2. – P. 60-63.
6.    Regarding the Standardization of Antihypertensive tablets / l.i. kucherenko, n.v. parniuk, z.b. moriak // Current Issues of Pharmaceutical and Medical Science and Practice. – 2015. –  No. 3. – P. 25-29.
7.    Regarding Conducting the "Dissolution" Test for Hypertril Tablets Using the HPLC Method / Kucherenko L.I., Moriak Z.B., Cherkovska L.H. // Current Issues of Pharmaceutical and Medical Science and Practice. - 2019. – Т.12, No.1 (29). - P.42-46.
8.    Validation of the quantitation methods of 1-(β-phenylethyl)-4-amino-1,2,4-triazole bromide substance by spectrophotometric method // Kucherenko L.I., Khromylova O.V., Parniuk N.V. // Asian Journal of Pharma-ceutical and Clinical Re-search. - Vol 11, No. 2. – 2018. - P.231-234.
9.    Kucherenko L. Bidnenko O. Khromylova O. Validation of the spectrophotometric method for the determination of quantitative composition of S-2,6-diagenoxic acid of 3-methyl-1,2,4-triazolyl-5-thioacetate. Asian J Pharm Clin Res. 2018; 11 (9): 91-94. doi.org/10.22159/ajpcr.2018.v11i9.22684
10.    Murugan S, Chandra Sekhar R. Method Development and Validation of Fingolimod in Bulk and Tablet Dosage Form by RP-HPLC. Research J. Pharm. and Tech. 2017; 10(8): 2573-2576. doi: 10.5958/0974-360X.2017.00456.5 
11.    Tejaswi Gilakamsetti, Poojitha Nalluri, Ramya Kuber Banoth. Development and Validation of a Novel RP-HPLC Method for Estimation of Bexagliflozin in Pure and Pharmaceutical Formulation. Research Journal of Pharmacy and Technology. 2024; 17(10): 4758-4. doi: 10.52711/0974-360X.2024.00733 
12.    Leena Sawaikar, Pankaj Kapupara. Development and Validation of a Stability indicating RP-HPLC Method for the Estimation of Chlorthalidone and Cilnidipine in Combined Pharmaceutical Dosage Form. Research J. Pharm. and Tech. 2020; 13(5): 2376-2380. doi: 10.5958/0974-360X.2020.00427.8 
13.    Priyanka M. Pandya, Pankaj P. Kapupara, Ketan V. Shah. Development and Validation of an Analytical Method for Simultaneous Estimation of Clotrimazole and its Impurity by RP-HPLC. Research J. Pharm. and Tech. 2018; 11(3): 894-898. doi: 10.5958/0974-360X.2018.00165.8 
14.    Shiv Kumar Gupta, Neetu Sachan, Phool Chandra, Arun Kumar Sharma. A Simple and Sophisticated RP-HPLC Approach for Quantifying of Irinotecan in API and in Pharmaceutical Dosage Form. Research Journal of Pharmacy and Technology. 2024; 17(10):4722-6. doi: 10.52711/0974-360X.2024.00728 
15.    Bhanu Biswas, Manish Kumar, Jai Bharti Sharma, Vipin Saini, Shailendra Bhatt. Method Development and Validation for Estimation of Teneligliptin in Tablet Dosage Form by RP-HPLC. Research J. Pharm. and Tech. 2020; 13(4): 1774-1778. doi: 10.5958/0974-360X.2020.00320.0 
16.    Baokar Shrikrishna, Ranpise Nisharani. Analytical Method Development and Validation for Simultaneous Estimation of Montelukast and Ebastine by HPLC. Research J. Pharm. and Tech. 2015; 8(1): Jan. 01-05. doi: 10.5958/0974-360X.2015.00001.3 
17.    P. Ravi Sankar, K. Saisneha Latha, A. Bhavani Sailu, SK. Taheera, B. Madhuri. Development and Validation of RP-HPLC Method for the Determination of Pazopanib Hydrochloride (A Tyrosine Kinase Inhibitor) in Pharmaceutical Dosage Form. Research J. Pharm. and Tech 2021; 14(3): 1549-1554. doi: 10.5958/0974-360X.2021.00273.0
18.    Palani Shanmugasundaram, Kamarapu S. K. RP-HPLC Method for the Simultaneous Estimation and Validation of Amlodipine Besylate and Atenolol in Bulk and Tablet Dosage Form in Biorelevant Dissolution Medium (Fassif). Research J. Pharm. and Tech 2017; 10(10): 3379-3385. doi: 10.5958/0974-360X.2017.00601.1 
19.    State Enterprise «Ukrainian Scientific Pharmacopoeial Center for Drug Quality». State Pharmacopoeia of Ukraine: in 3 volumes. 2nd edit. 2015; 1 – 1128 P.
20.    State Enterprise «Ukrainian Scientific Pharmacopoeial Center for Drug Quality». State Pharmacopoeia of Ukraine: in 3 volumes. 2nd edit. 2015; 2. – 724 P.
21.    State Enterprise «Ukrainian Scientific Pharmacopoeial Center for Drug Quality». State Pharmacopoeia of Ukraine: in 3 volumes. 2nd edit. 2015; 3. – 732 P.

Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

1.3
2021CiteScore
 
56th percentile
Powered by  Scopus


SCImago Journal & Country Rank

Journal Policies & Information


Recent Articles




Tags


Not Available